Related Experiment Video

Updated: Aug 31, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
06:49

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Prophylaxis of Candida and Aspergillus infections with oral administration of itraconazole

J Van Cutsem1

  • 1Janssen Research Foundation, Department of Bacteriology and Mycology, Beerse, Belgium.

Mycoses
|July 1, 1994
PubMed

Insights

Itraconazole demonstrates significant prophylactic efficacy against fungal infections like Candida and Aspergillus in animal models. This broad-spectrum antifungal may be a viable option for preventing opportunistic fungal infections in high-risk patients.

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Itraconazole is a broad-spectrum oral triazole antifungal with proven efficacy against various fungi.
  • Its pharmacokinetic profile suggests potential for prophylactic use in immunocompromised patients.
  • Opportunistic fungal infections pose a significant threat to at-risk individuals.

Purpose of the Study:

  • To evaluate the prophylactic efficacy of itraconazole against experimental Candida and Aspergillus infections.
  • To compare the prophylactic efficacy of itraconazole with Amphotericin B.
  • To determine the dose-dependent prophylactic effect of itraconazole.

Main Methods:

  • Animal models were used to test itraconazole's prophylactic efficacy against Candida albicans and Aspergillus infections.
  • Itraconazole was administered at single doses of 1.25 mg/kg or 2.5 mg/kg before fungal challenge.
  • Prophylactic efficacy was assessed by measuring protection rates, organ fungal burden, and survival.

Main Results:

  • Itraconazole prophylaxis protected 50% of rats against vaginal Candida albicans infection at tested doses.
  • In guinea pigs, itraconazole reduced organ Candida content and folliculitis in systemic candidosis.
  • Itraconazole prolonged survival in experimental invasive aspergillosis and was more efficacious than Amphotericin B.

Conclusions:

  • Itraconazole exhibits significant prophylactic efficacy in experimental models of candidosis and aspergillosis.
  • The prophylactic efficacy of itraconazole is dose-dependent.
  • Animal model results accurately predict clinical efficacy, suggesting itraconazole as a potential prophylactic agent for at-risk patients.

More Related Videos

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

Examination of Oral Candida Infection in Primary Sjögren's Syndrome Patients05:26

Examination of Oral Candida Infection in Primary Sjögren's Syndrome Patients

Published on: March 1, 2024

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...